Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics.

Literature DB >> 35373039

Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics.

Abstract

Entities: Chemical

Keywords: SGLT2i; diabetes and the kidney; diabetic kidney disease; diuretics; glucose; pharmaceutical preparations; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year: 2021 PMID： 35373039 PMCID： PMC8791327 DOI： 10.34067/KID.0000412021

Source DB: PubMed Journal: Kidney360 ISSN： 2641-7650

× No keyword cloud information.

15 in total

1. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal: Endocr Pract Date: 2018-01-17 Impact factor: 3.443

2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245

Review 3. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors: Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal: Eur Heart J Date: 2020-01-07 Impact factor: 29.983

4. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.

Authors: Rozalina G McCoy; Hayley J Dykhoff; Lindsey Sangaralingham; Joseph S Ross; Pinar Karaca-Mandic; Victor M Montori; Nilay D Shah
Journal: Diabetes Technol Ther Date: 2019-10-09 Impact factor: 6.118

5. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245

6. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors: Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal: N Engl J Med Date: 2019-04-14 Impact factor: 91.245

7. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors: Brendon L Neuen; Tamara Young; Hiddo J L Heerspink; Bruce Neal; Vlado Perkovic; Laurent Billot; Kenneth W Mahaffey; David M Charytan; David C Wheeler; Clare Arnott; Severine Bompoint; Adeera Levin; Meg J Jardine
Journal: Lancet Diabetes Endocrinol Date: 2019-09-05 Impact factor: 32.069

8. Dapagliflozin in Patients with Chronic Kidney Disease.

Authors: Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal: N Engl J Med Date: 2020-09-24 Impact factor: 91.245

9. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Authors: Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Peter Carson; James Januzzi; Subodh Verma; Hiroyuki Tsutsui; Martina Brueckmann; Waheed Jamal; Karen Kimura; Janet Schnee; Cordula Zeller; Daniel Cotton; Edimar Bocchi; Michael Böhm; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure; Nadia Giannetti; Stefan Janssens; Jian Zhang; Jose R Gonzalez Juanatey; Sanjay Kaul; Hans-Peter Brunner-La Rocca; Bela Merkely; Stephen J Nicholls; Sergio Perrone; Ileana Pina; Piotr Ponikowski; Naveed Sattar; Michele Senni; Marie-France Seronde; Jindrich Spinar; Iain Squire; Stefano Taddei; Christoph Wanner; Faiez Zannad
Journal: N Engl J Med Date: 2020-08-28 Impact factor: 176.079

10. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors: Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal: Diabetes Care Date: 2018-10-04 Impact factor: 19.112

5 in total

Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics.

1. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Review 3. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

4. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.

5. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

6. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

7. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

8. Dapagliflozin in Patients with Chronic Kidney Disease.

9. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

10. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1. A Call for Implementation Science: Achieving Equitable Access to SGLT2 Inhibitors.

Review 2. Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy.

Review 3. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.

4. Knowledge and practice of community pharmacists towards SGLT2 inhibitors.

Review 5. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.